ES2980256T3 - Formas cristalinas de un estimulador SGC - Google Patents

Formas cristalinas de un estimulador SGC Download PDF

Info

Publication number
ES2980256T3
ES2980256T3 ES19712427T ES19712427T ES2980256T3 ES 2980256 T3 ES2980256 T3 ES 2980256T3 ES 19712427 T ES19712427 T ES 19712427T ES 19712427 T ES19712427 T ES 19712427T ES 2980256 T3 ES2980256 T3 ES 2980256T3
Authority
ES
Spain
Prior art keywords
powder diffraction
ray powder
angles
crystalline
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19712427T
Other languages
English (en)
Spanish (es)
Inventor
Kwame Nti-Addae
Leena Prasad
Thomas Storz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tisento Therapeutics Inc
Original Assignee
Tisento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2980256(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tisento Therapeutics Inc filed Critical Tisento Therapeutics Inc
Application granted granted Critical
Publication of ES2980256T3 publication Critical patent/ES2980256T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES19712427T 2018-03-07 2019-03-07 Formas cristalinas de un estimulador SGC Active ES2980256T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
ES2980256T3 true ES2980256T3 (es) 2024-09-30

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19712427T Active ES2980256T3 (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulador SGC

Country Status (21)

Country Link
US (3) US11466015B2 (https=)
EP (1) EP3762389B1 (https=)
JP (1) JP7423539B2 (https=)
KR (1) KR102782810B1 (https=)
CN (1) CN111836812A (https=)
AU (1) AU2019231724B2 (https=)
BR (1) BR112020018212A2 (https=)
CA (1) CA3092683A1 (https=)
CL (5) CL2020002284A1 (https=)
CO (1) CO2020012493A2 (https=)
CR (1) CR20200458A (https=)
EA (1) EA202092109A1 (https=)
ES (1) ES2980256T3 (https=)
IL (1) IL276853B1 (https=)
MA (1) MA54638A (https=)
MX (5) MX2023004858A (https=)
PE (1) PE20210124A1 (https=)
PH (1) PH12020551394A1 (https=)
SG (1) SG11202008641WA (https=)
TW (1) TWI823903B (https=)
WO (1) WO2019173551A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
KR20210031931A (ko) * 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
EP4640676A1 (en) * 2022-12-21 2025-10-29 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof
AU2023412238A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费-阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n-芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2891976C (en) 2012-11-30 2020-07-21 Astellas Pharma Inc. Imidazopyridine compounds
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN107257796A (zh) * 2014-12-02 2017-10-17 拜耳医药股份有限公司 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
CR20220309A (es) * 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator

Also Published As

Publication number Publication date
JP7423539B2 (ja) 2024-01-29
MX2023004856A (es) 2023-11-24
US20230095799A1 (en) 2023-03-30
MX2023004858A (es) 2023-11-24
US20250115611A1 (en) 2025-04-10
CR20200458A (es) 2020-11-09
AU2019231724B2 (en) 2024-06-27
CL2021003530A1 (es) 2022-08-19
KR20200128708A (ko) 2020-11-16
EP3762389B1 (en) 2024-02-28
IL276853B1 (en) 2026-01-01
MX2020009183A (es) 2020-10-08
CL2021003531A1 (es) 2022-08-19
CL2021003536A1 (es) 2022-08-19
MX2023004857A (es) 2023-11-24
CL2020002284A1 (es) 2020-11-27
TW201940487A (zh) 2019-10-16
CN111836812A (zh) 2020-10-27
WO2019173551A1 (en) 2019-09-12
PH12020551394A1 (en) 2021-11-22
MX2023004855A (es) 2023-11-24
CO2020012493A2 (es) 2020-10-30
CA3092683A1 (en) 2019-09-12
US12122782B2 (en) 2024-10-22
MA54638A (fr) 2021-11-10
TWI823903B (zh) 2023-12-01
BR112020018212A2 (pt) 2020-12-29
IL276853A (en) 2020-10-29
US11466015B2 (en) 2022-10-11
EP3762389A1 (en) 2021-01-13
PE20210124A1 (es) 2021-01-19
CL2021000301A1 (es) 2021-06-18
JP2021515015A (ja) 2021-06-17
KR102782810B1 (ko) 2025-03-14
US20210115050A1 (en) 2021-04-22
AU2019231724A1 (en) 2020-10-08
WO2019173551A8 (en) 2020-06-11
EA202092109A1 (ru) 2021-03-04
SG11202008641WA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US12122782B2 (en) Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
US20250129060A1 (en) Solid forms of an sgc stimulator
US20240360164A1 (en) Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators
CA3029333C (en) Solid forms of an sgc stimulator
HK40042071A (en) Crystalline forms of an sgc stimulator
HK40042071B (en) Crystalline forms of an sgc stimulator
EA048931B1 (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC
WO2021195403A1 (en) Deuterated sgc stimulators
EA045683B1 (ru) ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC
HK40007030B (en) Solid forms of an sgc stimulator
HK40007030A (en) Solid forms of an sgc stimulator
OA19465A (en) Solid forms of an SGC stimulator.